Chromatin modifications associated with diabetes

Journal of Cardiovascular Translational Research

Volumn 5, Issue 4, 2012, Pages 399-412

  Keating, Samuel T ^a   El Osta, Assam ^a,b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Diabetes; Diabetic complications; DNA methylation; Epigenetic gene regulation; Histone acetylation; Histone methylation; Hyperglycaemia; Metabolic memory; Set7 methyltransferase

Indexed keywords

HISTONE H3; METHYLTRANSFERASE;

AMINO TERMINAL SEQUENCE; ARTICLE; CHROMATIN MODIFICATION; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DNA METHYLATION; DNA MODIFICATION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLYCEMIC CONTROL; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES COMPLICATIONS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBIN A, GLYCOSYLATED; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS;

ANIMALIA;

EID: 84866076182     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9380-9     Document Type: Article

References (132)

1. International Diabetes Federation. (2009). IDF diabetes atlas (4th ed.). Brussels: International Diabetes Federation.
2. Shaw, J. E., & Chisholm, D. J. (2003). 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. The Medical Journal of Australia, 179(7), 379-383.
3. El-Osta, A. (2012). Glycemic memory. Current Opinion in Lipidology, 23(1), 24-29.
4. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813-820.
5. Anonymous (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine, 329(14), 977-986.
6. Prospective, U. K. (1991). Diabetes study (UKPDS). VIII. Study design, progress and performance. Diabetologia, 34(12), 877-890.
7. The Diabetes Control and Complications Trial (DCCT). (1986). Design and methodologic considerations for the feasibility phase. The DCCT research group. Diabetes, 35(5), 530-545.
8. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology ofDiabetes Interventions and Complications (EDIC) study. JAMA, 290(16), 2159-2167.
9. Nathan, D. M., Cleary, P. A., Backlund, J. Y., et al. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine, 353(25), 2643-2653.
10. Cleary, P. A., Orchard, T. J., Genuth, S., et al. (2006). The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes, 55(12), 3556-3565.
11. Nathan, D. M., Lachin, J., Cleary, P., et al. (2003). Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. The New England Journal of Medicine, 348 (23), 2294-2303.
12. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine, 359 (15), 1577-1589.
13. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA, 287 (19), 2563-2569.
14. Engerman, R. L., & Kern, T. S. (1987). Progression of incipient diabetic retinopathy during good glycemic control. Diabetes, 36 (7), 808-812.
15. Hammes, H. P., Klinzing, I., Wiegand, S., Bretzel, R. G., Cohen, A. M., & Federlin, K. (1993). Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Investigative Ophthalmology & Visual Science, 34(6), 2092-2096.
16. Kowluru, R. A. (2003). Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes, 52(3), 818-823.
17. El-Osta, A., Brasacchio, D., Yao, D., et al. (2008). Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of Experimental Medicine, 205(10), 2409-2417.
18. Thurberg, B. L., & Collins, T. (1998). The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Current Opinion in Lipidology, 9(5), 387-396.
19. Lewis, P., Stefanovic, N., Pete, J., et al. (2007). Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation, 115(16), 2178-2187.
20. Bakker, W., Eringa, E. C., Sipkema, P., & van Hinsbergh, V. W. (2009). Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and Tissue Research, 335(1), 165-189.
21. Roy, S., Sala, R., Cagliero, E., & Lorenzi, M. (1990). Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proceedings of the National Academy of Sciences of the United States of America, 87(1), 404-408.
22. Nishikawa, T., Edelstein, D., Du, X. L., et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404(6779), 787-790.
23. Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54(6), 1615-1625.
24. Ihnat, M. A., Thorpe, J. E., Kamat, C. D., et al. (2007). Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia, 50(7), 1523-1531.
25. Turner, B. M. (2002). Cellular memory and the histone code. Cell, 111(3), 285-291.
26. Bird, A. (2007). Perceptions of epigenetics. Nature, 447(7143), 396-398.
27. Jenuwein, T., & Allis, C. D. (2001). Translating the histone code. Science, 293(5532), 1074-1080.
28. Greer, E. L., Maures, T. J., Ucar, D., et al. (2011). Transgenerational epigenetic inheritance of longevity in Caenorhabditis elegans. Nature, 479(7373), 365-371.
29. Braunschweig, M., Jagannathan, V., Gutzwiller, A., & Bee, G. (2012). Investigations on transgenerational epigenetic response down the male line in f2 pigs. PLoS One, 7(2), e30583.
30. Iguchi-Ariga, S. M., & Schaffner, W. (1989). CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes & Development, 3(5), 612-619.
31. Pennings, S., Allan, J., & Davey, C. S. (2005). DNA methylation, nucleosome formation and positioning. Briefings in Functional Genomics & Proteomics, 3(4), 351-361.
32. Chodavarapu, R. K., Feng, S., Bernatavichute, Y. V., et al. (2010). Relationship between nucleosome positioning and DNA methylation. Nature, 466(7304), 388-392.
33. Fuks, F., Hurd, P. J.,Wolf, D., Nan, X., Bird, A. P., & Kouzarides, T. (2003). The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. Journal of Biological Chemistry, 278(6), 4035-4040.
34. Meehan, R. R., Lewis, J. D., & Bird, A. P. (1992). Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Research, 20(19), 5085-5092.
35. Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & Development, 13(15), 1924-1935.
36. Maier, S., & Olek, A. (2002). Diabetes: a candidate disease for efficient DNA methylation profiling. Journal of Nutrition, 132(8 Suppl), 2440S-2443S.
37. Reik, W., Dean, W., & Walter, J. (2001). Epigenetic reprogramming in mammalian development. Science, 293(5532), 1089-1093.
38. Thompson, R. F., Fazzari, M. J., Niu, H., Barzilai, N., Simmons, R. A., & Greally, J. M. (2010). Experimental intrauterine growth restriction induces alterations in DNA methylation and gene expression in pancreatic islets of rats. Journal of Biological Chemistry, 285(20), 15111-15118.
39. Einstein, F., Thompson, R. F., Bhagat, T. D., et al. (2010). Cytosine methylation dysregulation in neonates following intrauterine growth restriction. PLoS One, 5(1), e8887.
40. Kuroda, A., Rauch, T. A., Todorov, I., et al. (2009). Insulin gene expression is regulated by DNA methylation. PLoS One, 4(9), e6953.
41. Stenvinkel, P., Karimi, M., Johansson, S., et al. (2007). Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? Journal of Internal Medicine, 261 (5), 488-499.
42. Brennan, E. P., Ehrich, M., O'Donovan, H., et al. (2010). DNA methylation profiling in cell models of diabetic nephropathy. Epigenetics, 5(5), 396-401.
43. Chan, Y., Fish, J. E., D'Abreo, C., et al. (2004). The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. Journal of Biological Chemistry, 279(33), 35087-35100.
44. Bell, C. G., Teschendorff, A. E., Rakyan, V. K., Maxwell, A. P., Beck, S., & Savage, D. A. (2010). Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Medical Genomics, 3, 33.
45. Kim, M., Long, T. I., Arakawa, K., Wang, R., Yu, M. C., & Laird, P. W. (2010). DNA methylation as a biomarker for cardiovascular disease risk. PLoS One, 5(3), e9692.
46. Hiltunen, M. O., Turunen, M. P., Hakkinen, T. P., et al. (2002). DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vascular Medicine, 7(1), 5-11.
47. Hiltunen, M. O., & Yla-Herttuala, S. (2003). DNA methylation, smooth muscle cells, and atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(10), 1750-1753.
48. Laukkanen, M. O., Mannermaa, S., Hiltunen, M. O., et al. (1999). Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(9), 2171-2178.
49. Rakyan, V. K., Beyan, H., Down, T. A., et al. (2011). Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genetics, 7(9), e1002300.
50. Luger, K. (2006). Dynamic nucleosomes. Chromosome Research, 14(1), 5-16.
51. Strahl, B. D., & Allis, C. D. (2000). The language of covalent histone modifications. Nature, 403(6765), 41-45.
52. Malik, H. S., & Henikoff, S. (2003). Phylogenomics of the nucleosome. Natural Structural Biology, 10(11), 882-891.
53. Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693-705.
54. An, W. (2007). Histone acetylation and methylation: combinatorial players for transcriptional regulation. Subcellular Biochemistry, 41, 351-369.
55. Roth, S. Y., Denu, J. M., & Allis, C. D. (2001). Histone acetyltransferases. Annual Review of Biochemistry, 70, 81-120.
56. Shogren-Knaak, M., Ishii, H., Sun, J. M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006). Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science, 311 (5762), 844-847.
57. Braunstein, M., Rose, A. B., Holmes, S. G., Allis, C. D., & Broach, J. R. (1993). Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes & Development, 7(4), 592-604.
58. Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. Nature, 389(6649), 349-352.
59. Eberharter, A.,& Becker, P. B. (2002). Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Reports, 3(3), 224-229.
60. Roh, T. Y., Cuddapah, S., & Zhao, K. (2005). Active chromatin domains are defined by acetylation islands revealed by genomewide mapping. Genes & Development, 19(5), 542-552.
61. Roh, T. Y., Wei, G., Farrell, C. M., & Zhao, K. (2007). Genomewide prediction of conserved and nonconserved enhancers by histone acetylation patterns. Genome Research, 17(1), 74-81.
62. de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemistry Journal, 370(Pt 3), 737-749.
63. Wade, P. A., & Wolffe, A. P. (1997). Histone acetyltransferases in control. Current Biology, 7(2), R82-R84.
64. Chen, S., Feng, B., George, B., Chakrabarti, R., Chen, M., & Chakrabarti, S. (2010). Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. American Journal of Physiology, Endocrinology and Metabolism, 298(1), E127-E137.
65. Mosley, A. L., & Ozcan, S. (2003). Glucose regulates insulin gene transcription by hyperacetylation of histone h4. Journal of Biological Chemistry, 278(22), 19660-19666.
66. Mosley, A. L., Corbett, J. A., & Ozcan, S. (2004). Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Molecular Endocrinology, 18(9), 2279-2290.
67. Suganuma, T., & Workman, J. L. (2011). Signals and combinatorial functions of histone modifications. Annual Review of Biochemistry, 80, 473-499.
68. Cheung, P., & Lau, P. (2005). Epigenetic regulation by histone methylation and histone variants. Molecular Endocrinology, 19 (3), 563-573.
69. Zhang, Y., & Reinberg, D. (2001). Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes & Development, 15(18), 2343-2360.
70. Qian, C., & Zhou, M. M. (2006). SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cellular and Molecular Life Sciences, 63(23), 2755-2763.
71. Tschiersch, B., Hofmann, A., Krauss, V., Dorn, R., Korge, G., & Reuter, G. (1994). The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes. EMBO Journal, 13(16), 3822-3831.
72. Stassen, M. J., Bailey, D., Nelson, S., Chinwalla, V., & Harte, P. J. (1995). The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins. Mechanisms of Development, 52(2-3), 209-223.
73. Jenuwein, T., Laible, G., Dorn, R., & Reuter, G. (1998). SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cellular and Molecular Life Sciences, 54(1), 80-93.
74. Sims, R. J., 3rd, Nishioka, K., & Reinberg, D. (2003). Histone lysine methylation: a signature for chromatin function. Trends in Genetics, 19(11), 629-639.
75. Boggs, B. A., Cheung, P., Heard, E., Spector, D. L., Chinault, A. C., & Allis, C. D. (2002). Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nature Genetics, 30(1), 73-76.
76. Noma, K., Allis, C. D., & Grewal, S. I. (2001). Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science, 293(5532), 1150-1155.
77. Syreeni, A., El-Osta, A., Forsblom, C., et al. (2011). Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes, 60(11), 3073-3080.
78. Wang, H., Cao, R., Xia, L., et al. (2001). Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Molecular Cell, 8(6), 1207-1217.
79. Nishioka, K., Chuikov, S., Sarma, K., et al. (2002). Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes & Development, 16(4), 479-489.
80. Zegerman, P., Canas, B., Pappin, D., & Kouzarides, T. (2002). Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) repressor complex. Journal of Biological Chemistry, 277(14), 11621-11624.
81. Deering, T. G., Ogihara, T.,Trace, A. P.,Maier, B.,&Mirmira,R. G. (2009).Methyltransferase Set7/9maintains transcription and euchromatin structure at islet-enriched genes. Diabetes, 58(1), 185-193.
82. Ogihara, T., Vanderford, N. L., Maier, B., Stein, R. W., & Mirmira, R. G. (2009). Expression and function of Set7/9 in pancreatic islets. Islets, 1(3), 269-272.
83. Francis, J., Chakrabarti, S. K., Garmey, J. C., & Mirmira, R. G. (2005). Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription. Journal of Biological Chemistry, 280(43), 36244-36253.
84. Li, Y., Reddy, M. A., Miao, F., et al. (2008). Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NFkappaB- dependent inflammatory genes. Relevance to diabetes and inflammation. Journal of Biological Chemistry, 283(39), 26771-26781.
85. Brasacchio, D., Okabe, J., Tikellis, C., et al. (2009). Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes, 58(5), 1229-1236.
86. Okabe, J., Orlowski, C., Balcerczyk, A., et al. (2012). Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circulation Research, 110, 1067-1076.
87. Ea, C. K., & Baltimore, D. (2009). Regulation of NF-kappaB activity through lysine monomethylation of p65. Proceedings of the National Academy of Sciences of the United States of America, 106(45), 18972-18977.
88. Yang, X. D., Huang, B., Li, M., Lamb, A., Kelleher, N. L., & Chen, L. F. (2009). Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO Journal, 28(8), 1055-1066.
89. Sun, G., Reddy, M. A., Yuan, H., Lanting, L., Kato, M., & Natarajan, R. (2010). Epigenetic histone methylation modulates fibrotic gene expression. Journal of the American Society of Nephrology, 21(12), 2069-2080.
90. Verrecchia, F., Chu, M. L., & Mauviel, A. (2001). Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. Journal of Biological Chemistry, 276(20), 17058-17062.
91. Chung, A. C., Zhang, H., Kong, Y. Z., et al. (2010). Advanced glycation end-products induce tubular CTGF via TGF-betaindependent Smad3 signaling. Journal of the American Society of Nephrology, 21(2), 249-260.
92. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., & Gauthier, J. M. (1998). Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO Journal, 17(11), 3091-3100.
93. Yang, F., Chung, A. C., Huang, X. R., & Lan, H. Y. (2009). Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension, 54(4), 877-884.
94. Lan, H. Y. (2011). Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. International Journal of Biological Sciences, 7(7), 1056-1067.
95. Fujimoto, M., Maezawa, Y., Yokote, K., et al. (2003). Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochemical and Biophysical Research Communications, 305(4), 1002-1007.
96. Li, J. H., Huang, X. R., Zhu, H. J., et al. (2004). Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. The FASEB Journal, 18(1), 176-178.
97. Wang, W., Huang, X. R., Canlas, E., et al. (2006). Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circulation Research, 98(8), 1032-1039.
98. Martens, J. H., Verlaan, M., Kalkhoven, E., & Zantema, A. (2003). Cascade of distinct histone modifications during collagenase gene activation. Molecular and Cellular Biology, 23(5), 1808-1816.
99. Pradhan, S., Chin, H. G., Esteve, P. O., & Jacobsen, S. E. (2009). SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics, 4(6), 383-387.
100. Dhayalan, A., Kudithipudi, S., Rathert, P., & Jeltsch, A. (2011). Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chemical Biology, 18(1), 111-120.
101. Chuikov, S., Kurash, J. K.,Wilson, J. R., et al. (2004). Regulation of p53 activity through lysine methylation. Nature, 432(7015), 353-360.
102. Esteve, P. O., Chin, H. G., Benner, J., et al. (2009). Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 106(13), 5076-5081.
103. Subramanian, K., Jia, D., Kapoor-Vazirani, P., et al. (2008). Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Molecular Cell, 30(3), 336-347.
104. Kouskouti, A., Scheer, E., Staub, A., Tora, L., & Talianidis, I. (2004). Gene-specific modulation of TAF10 function by SET9- mediated methylation. Molecular Cell, 14(2), 175-182.
105. Yang, J., Huang, J., Dasgupta, M., et al. (2010). Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21499-21504.
106. Saraheimo, M., Teppo, A. M., Forsblom, C., Fagerudd, J., & Groop, P. H. (2003). Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia, 46(10), 1402-1407.
107. Shikano, M., Sobajima, H., Yoshikawa, H., et al. (2000). Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron, 85(1), 81-85.
108. Tuttle, H. A., Davis-Gorman, G., Goldman, S., Copeland, J. G., & McDonagh, P. F. (2004). Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease. Journal of Diabetes and its Complications, 18(6), 343-351.
109. Mirza, S., Hossain, M., Mathews, C., et al. (2012). Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine, 57(1), 136-142.
110. Berthier, C. C., Zhang, H., Schin, M., et al. (2009). Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes, 58(2), 469-477.
111. Simon, A. R., Rai, U., Fanburg, B. L., & Cochran, B. H. (1998). Activation of the JAK-STAT pathway by reactive oxygen species. American Journal of Physiology, 275(6 Pt 1), C1640-C1652.
112. Huang, J. S., Guh, J. Y., Chen, H. C., Hung, W. C., Lai, Y. H., & Chuang, L. Y. (2001). Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. Journal of Cellular Biochemistry, 81(1), 102-113.
113. Lu, T. C., Wang, Z. H., Feng, X., et al. (2009). Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney International, 76(1), 63-71.
114. Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004). The JAK/STAT signaling pathway. Journal of Cell Science, 117(Pt 8), 1281-1283.
115. Yasukawa, H., Ohishi, M., Mori, H., et al. (2003). IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nature Immunology, 4(6), 551-556.
116. Ortiz-Munoz, G., Lopez-Parra, V., Lopez-Franco, O., et al. (2010). Suppressors of cytokine signaling abrogate diabetic nephropathy. Journal of the American Society of Nephrology, 21(5), 763-772.
117. Gaughan, L., Stockley, J., Wang, N., et al. (2011). Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Research, 39(4), 1266-1279.
118. O'Meara, N. M., Blackman, J. D., Ehrmann, D. A., et al. (1993). Defects in beta-cell function in functional ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 76 (5), 1241-1247.
119. Dunaif, A., & Finegood, D. T. (1996). beta-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81(3), 942-947.
120. Liu, S., Navarro, G., & Mauvais-Jarvis, F. (2010). Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One, 5(6), e11302.
121. Pirola, L., Balcerczyk, A., Tothill, R. W., et al. (2011). Genomewide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Research, 21(10), 1601-1615.
122. Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058-1070.
123. Noyman, I., Marikovsky, M., Sasson, S., et al. (2002). Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide, 7(3), 187-193.
124. Zhang, Q., Malik, P., Pandey, D., et al. (2008). Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(9), 1627-1633.
125. Du, X., Edelstein, D., Obici, S., Higham, N., Zou, M. H., & Brownlee, M. (2006). Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. The Journal of Clinical Investigation, 116 (4), 1071-1080.
126. Shen, X., Zheng, S., Metreveli, N. S., & Epstein, P. N. (2006). Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes, 55(3), 798-805.
127. Otero, P., Bonet, B., Herrera, E., & Rabano, A. (2005). Development of atherosclerosis in the diabetic BALB/c mice. Prevention with vitamin E administration. Atherosclerosis, 182(2), 259-265.
128. Zhang, Y., Wada, J., Hashimoto, I., et al. (2006). Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. Journal of the American Society of Nephrology, 17(4), 1090-1101.
129. DeRubertis, F. R., Craven, P. A., & Melhem, M. F. (2007). Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism, 56(9), 1256-1264.
130. Kowluru, R. A., Kowluru, V., Xiong, Y., & Ho, Y. S. (2006). Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radical Biology & Medicine, 41(8), 1191-1196.
131. Vincent, A. M., Russell, J. W., Sullivan, K. A., et al. (2007). SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Experimental Neurology, 208(2), 216-227.
132. Kurash, J. K., Lei, H., Shen, Q., et al. (2008). Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Molecular Cell, 29(3), 392-400.